Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2024

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Vascular Endothelial Growth Factor Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vascular Endothelial Growth Factor Inhibitors Understanding

Vascular Endothelial Growth Factor Inhibitors: Overview

Angiogenesis, or formation of new blood capillaries from preexisting vessels, plays both beneficial and damaging roles in the organism. It is a result of a complex balance of positive and negative regulators, and vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors involved in tumor angiogenesis. VEGF increases vascular permeability, which might facilitate tumor dissemination via the circulation causing a greater delivery of oxygen and nutrients; it recruits circulating endothelial precursor cells, and acts as a survival factor for immature tumor blood vessels. The endotheliotropic activities of VEGF are mediated through the VEGF-specific tyrosine-kinase receptors: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF and its receptors play a central role in tumor angiogenesis, and therefore the blockade of this pathway is a promising therapeutic strategy for inhibiting angiogenesis and tumor growth. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function.

""Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Endothelial Growth Factor Inhibitors pipeline landscape is provided which includes the disease overview and Vascular Endothelial Growth Factor Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Vascular Endothelial Growth Factor Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Endothelial Growth Factor Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Endothelial Growth Factor Inhibitors.

Vascular Endothelial Growth Factor Inhibitors Emerging Drugs Chapters

This segment of the Vascular Endothelial Growth Factor Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Endothelial Growth Factor Inhibitors Emerging Drugs

• KSI-301: Kodiak Sciences

KSI-301 is a novel anti-VEGF biologic built on Kodiak Sciences propriety antibody biopolymer conjugate (ABC) platform. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their wet AMD with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. It is currently in Phase III stage of development for the treatment of wet AMD, Diabetic macular edema, Retinal vein occlusion and Diabetic retinopathy. It is being developed by Kodiak Sciences.

• ONS-5010: Outlook Therapeutics

ONS-5010 / Lytenava (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab-vikg under development to be administered as an intravitreal injection for the treatment of wet AMD and other approved retinal diseases. It is currently in Phase III stage of development for the treatment of wet AMD and is being developed by Outlook Therapeutics.

• ADVM-022: Adverum Biotechnologies

ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 (AAV.7m8-aflibercept) is administered as a single, in-office intravitreal (IVT) injection, designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections, and improve vision outcomes for patients with wet age-related macular degeneration (wet AMD). It is being developed by Adverum Biotechnologies for wet AMD.

Further product details are provided in the report……..

Vascular Endothelial Growth Factor Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Endothelial Growth Factor Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Vascular Endothelial Growth Factor Inhibitors

There are approx. 40+ key companies which are developing the therapies for Vascular Endothelial Growth Factor Inhibitors. The companies which have their Vascular Endothelial Growth Factor Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Kodiak Sciences.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Vascular Endothelial Growth Factor Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Endothelial Growth Factor Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor Inhibitors drugs.

Vascular Endothelial Growth Factor Inhibitors Report Insights

• Vascular Endothelial Growth Factor Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vascular Endothelial Growth Factor Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vascular Endothelial Growth Factor Inhibitors drugs?
• How many Vascular Endothelial Growth Factor Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Endothelial Growth Factor Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Endothelial Growth Factor Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Endothelial Growth Factor Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Adverum Biotechnologies
• Outlook Therapeutics
• Sandoz
• Boehringer Ingelheim
• Allarity Therapeutics
• Konruns Pharmaceutical
• Kodiak Sciences

Key Products

• ADVM-022
• ONS-5010
• SOK583A1
• BI 836880
• Dovitinib
• CX1003
• KSI-301
• KSI-501